ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Sabine Schmid; Georgia Dimopoulou; Paul van Schil; David König; Laetitia Mauti; Malinda Itchins; Martin Früh; Kersti Oselin; Lorenza Landi; Maurice Pérol; Sanjay Popat; Clemens Aigner; Patrick Forde; Wouter K de Jong; Heidi Roschitzki-Voser; Eva Grolimund; Barbara Ruepp; Benjamin Solomon; Stephen Finn; Urania Dafni; Rolf Stahel; Solange Peters

doi:10.1016/j.lungcan.2025.108635

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

Sabine Schmid
, Georgia Dimopoulou
, Paul van Schil
, David König
, Laetitia Mauti
, Malinda Itchins
, Martin Früh
, Kersti Oselin
, Lorenza Landi
, Maurice Pérol
, Sanjay Popat
, Clemens Aigner
, Patrick Forde
, Wouter K de Jong
, Heidi Roschitzki-Voser
, Eva Grolimund
, Barbara Ruepp
, Benjamin Solomon
, Stephen Finn
, Urania Dafni

Rolf Stahel, Solange Peters^*,

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

14 Downloads (Pure)

Original language	English
Article number	108635
Journal	Lung Cancer
Volume	206
Early online date	23 Jun 2025
DOIs	https://doi.org/10.1016/j.lungcan.2025.108635
Publication status	Published - Aug 2025

Access to Document

10.1016/j.lungcan.2025.108635Licence: CC BY

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLCFinal published version, 467 KBLicence: CC BY

Cite this

Schmid, S., Dimopoulou, G., van Schil, P., König, D., Mauti, L., Itchins, M., Früh, M., Oselin, K., Landi, L., Pérol, M., Popat, S., Aigner, C., Forde, P., de Jong, W. K., Roschitzki-Voser, H., Grolimund, E., Ruepp, B., Solomon, B., Finn, S. (2025). ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC. Lung Cancer, 206, Article 108635. https://doi.org/10.1016/j.lungcan.2025.108635

@article{fda5f2a2c8d8465c98d072d4575cfd2a,

title = "ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC",

author = "Sabine Schmid and Georgia Dimopoulou and \{van Schil\}, Paul and David K{\"o}nig and Laetitia Mauti and Malinda Itchins and Martin Fr{\"u}h and Kersti Oselin and Lorenza Landi and Maurice P{\'e}rol and Sanjay Popat and Clemens Aigner and Patrick Forde and \{de Jong\}, \{Wouter K\} and Heidi Roschitzki-Voser and Eva Grolimund and Barbara Ruepp and Benjamin Solomon and Stephen Finn and Urania Dafni and Rolf Stahel and Solange Peters",

year = "2025",

month = aug,

doi = "10.1016/j.lungcan.2025.108635",

language = "English",

volume = "206",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

}

Schmid, S, Dimopoulou, G, van Schil, P, König, D, Mauti, L, Itchins, M, Früh, M, Oselin, K, Landi, L, Pérol, M, Popat, S, Aigner, C, Forde, P, de Jong, WK, Roschitzki-Voser, H, Grolimund, E, Ruepp, B, Solomon, B, Finn, S, Dafni, U, Stahel, R, Peters, S 2025, 'ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC', Lung Cancer, vol. 206, 108635. https://doi.org/10.1016/j.lungcan.2025.108635

ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC. / Schmid, Sabine; Dimopoulou, Georgia; van Schil, Paul et al.
In: Lung Cancer, Vol. 206, 108635, 08.2025.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - ETOP 25-23 ADOPT-lung

T2 - An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC

AU - Schmid, Sabine

AU - Dimopoulou, Georgia

AU - van Schil, Paul

AU - König, David

AU - Mauti, Laetitia

AU - Itchins, Malinda

AU - Früh, Martin

AU - Oselin, Kersti

AU - Landi, Lorenza

AU - Pérol, Maurice

AU - Popat, Sanjay

AU - Aigner, Clemens

AU - Forde, Patrick

AU - de Jong, Wouter K

AU - Roschitzki-Voser, Heidi

AU - Grolimund, Eva

AU - Ruepp, Barbara

AU - Solomon, Benjamin

AU - Finn, Stephen

AU - Dafni, Urania

AU - Stahel, Rolf

AU - Peters, Solange

PY - 2025/8

Y1 - 2025/8

U2 - 10.1016/j.lungcan.2025.108635

DO - 10.1016/j.lungcan.2025.108635

M3 - Article

C2 - 40582281

SN - 0169-5002

VL - 206

JO - Lung Cancer

JF - Lung Cancer

M1 - 108635

ER -

Schmid S, Dimopoulou G, van Schil P, König D, Mauti L, Itchins M et al. ETOP 25-23 ADOPT-lung: An international, multicentre, open-label randomised phase III trial to evaluate the benefit of adding adjuvant durvalumab after neoadjuvant chemotherapy plus durvalumab in patients with stage IIB-IIIB (N2) resectable NSCLC. Lung Cancer. 2025 Aug;206:108635. Epub 2025 Jun 23. doi: 10.1016/j.lungcan.2025.108635